$mbio is putting up a fight. Looking like it could really run.
Stock Markets
24,748,398 Views |
233447 Replies |
Last: 1 hr ago by Heineken-Ashi
BBIG doing a thing for anyone that got in that a while back
reloading NFLX. Watch closely for stop.
You don’t trade for money, you trade for freedom.
MBIO rocket coming up!
I just reduced my position there. Was far from net free as got in late but was able to get out at breakeven (including premium profit). Wanted to go more cash heading into September, wasnt comfortable with my risk so decided to simply lower position.
Will keep working towards net free on remaining shares and will buy back in if it dips.
I believe in stock and trust OA but had to think about market, my personal risk, position size, etc
I just reduced my position there. Was far from net free as got in late but was able to get out at breakeven (including premium profit). Wanted to go more cash heading into September, wasnt comfortable with my risk so decided to simply lower position.
Will keep working towards net free on remaining shares and will buy back in if it dips.
I believe in stock and trust OA but had to think about market, my personal risk, position size, etc
$30,000 Millionaire said:
reloading NFLX. Watch closely for stop.
Couple of candles under the 8 EMA (5-minute). Is this your stop our point?
Ernest Tucker said:$30,000 Millionaire said:
reloading NFLX. Watch closely for stop.
Couple of candles under the 8 EMA (5-minute). Is this your stop our point?
You don’t trade for money, you trade for freedom.
You don’t trade for money, you trade for freedom.
if you've made some $$ on anything I've suggested today - do something nice for a random person.
You don’t trade for money, you trade for freedom.
easy gains here on NFLX if you want to take them. I think this may have another leg up. Trail your stops.
You don’t trade for money, you trade for freedom.
Charismatic Megafauna
Joined:
May 22, 2017
Posts:
7,972
How long do you want to ignore this user?
AG
2 ideas:
I bought some expiring mvis15.5 calls for .05, it made a run at 15 earlier and i think it could go if it breaks it
I have an order in for some expiring spy 446/448 spreads for .3. If the market goes haywire and corrects maybe these can fill before we get back on track
Furiously trading expiring vxx calls today, really only intended to buy some to flip when jpow goes on, but turned 10-20% a few times already
I bought some expiring mvis15.5 calls for .05, it made a run at 15 earlier and i think it could go if it breaks it
I have an order in for some expiring spy 446/448 spreads for .3. If the market goes haywire and corrects maybe these can fill before we get back on track
Furiously trading expiring vxx calls today, really only intended to buy some to flip when jpow goes on, but turned 10-20% a few times already
$30,000 Millionaire said:
if you've made some $$ on anything I've suggested today - do something nice for a random person.
My paypal is RandomPerson03@yahoo.com
$NFLX is annoying now.
You don’t trade for money, you trade for freedom.
$30,000 Millionaire said:
if you've made some $$ on anything I've suggested today - do something nice for a random person.
Too busy to monitor intraday but you were spot on with some that I reviewed. Look forward to more lessons from 30k and a fresh start going into next week!
SAVA seems fun.
Quote:
Quanterix Refutes Claim It Prepared Disputed Data Charts Presented by Cassava Sciences to Alzheimer's Association
BY MT Newswires
9:54 AM ET 08/27/2021
09:54 AM EDT, 08/27/2021 (MT Newswires) -- Quanterix ( QTRX ) said in a statement Friday that it didn't interpret the test results or prepare data presented by Cassava Sciences' ( SAVA ) at the Alzheimer's Association International Conference.
Instead, Quanterix ( QTRX ) said it had previously tested samples provided by Cassava.
Cassava said in a statement on Wednesday, which was released to refute allegations questioning its scientific integrity, that Quanterix ( QTRX ) "generated" data on a drug to treat Alzheimer's, which was then presented at the conference.
"Cassava previously engaged Quanterix ( QTRX )' Accelerator laboratory to perform sample testing based on blinded samples provided by Cassava," Quanterix ( QTRX ) said in its statement. "Quanterix ( QTRX ) or its employees did not interpret the test results or prepare the data charts presented by Cassava at the Alzheimer's Association International Conference (AAIC) in July 2021 or otherwise."
Allegations were made against Cassava that disputed the company's trial data of the simufilam drug candidate. Cassava said in its Wednesday statement that those allegations are "false and misleading."
"As a science company, we champion facts that can be evaluated and verified," Cassava Chief Executive Remi Barbier said in the statement. "This helps people make informed choices. It is important for stakeholders to separate fact from fiction, which is why we wish to address allegations head-on."
Shares of Quanterix ( QTRX ) were up 7.2% in early trading, while Cassava shares plunged by 16%.
Price: 49.26, Change: +3.30, Percent Change: +7.17
This headline seems very misleading.
i'm still in NFLX. this ten min candle is the deciding candle.
You don’t trade for money, you trade for freedom.
$SAVA Riley defending it: pic.twitter.com/IP1SNi99Rx
— StockAuthority (@StockAuthority) August 27, 2021
I probably need to re-read this and just stopping looking at SAVA, ouch.
added some 9/1 447 SPY puts - small hedge
Any chance their is a late run with MSFT?
Lotto style $302.50 sitting at .06 right now seems like very little downside but maybe huge upside? It keeps pressing down today though.
Lotto style $302.50 sitting at .06 right now seems like very little downside but maybe huge upside? It keeps pressing down today though.
Farmer @ Johnsongrass, TX
Joined:
Sep 25, 2017
Posts:
5,415
How long do you want to ignore this user?
It is a misleading headline.
The conspiracy side of me wants to say it's cleverly written articles meant to hit SAVA.
The logical side of me says these authors have no clue how things work in the world and just disregard the articles until the FDA kicks them in the nutsack.
Side Note: I have not found an investment house that has changed their target price on SAVA.
The conspiracy side of me wants to say it's cleverly written articles meant to hit SAVA.
The logical side of me says these authors have no clue how things work in the world and just disregard the articles until the FDA kicks them in the nutsack.
Side Note: I have not found an investment house that has changed their target price on SAVA.
Anybody notice ELOX today up 5% so far?
Finally past my cost basis which makes it more comfortable to hold longer now.
Finally past my cost basis which makes it more comfortable to hold longer now.
January call spreads on SAVA are pretty cheap right now.
C130/140s are 1.00
If FDA clears SAVA and next data release is good, this could be a 10-bagger. If not, you lose $100.
C130/140s are 1.00
If FDA clears SAVA and next data release is good, this could be a 10-bagger. If not, you lose $100.
so this is the hard part about trading. $NFLX is holding that support so far. What do you do?
You don’t trade for money, you trade for freedom.
Cassava Sciences Releases Statement Regarding Plasma p-tau Analysis from a Previously Disclosed Phase 2b Clinical Study in Alzheimer's Patients
GLOBENEWSWIRE 10:31 AM ET 8/27/2021
AUSTIN, Texas, Aug. 27, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc.(SAVA) , a biotechnology company focused on Alzheimer's disease, today released a statement regarding plasma p-tau analysis from a previously disclosed randomized, controlled Phase 2b clinical study in patients with Alzheimer's disease. For this study, Cassava Sciences(SAVA) contracted with Quanterix Corp., a highly regarded, independent laboratory, to perform sample testing on blinded samples.
The Phase 2b clinical study was conducted by Cassava Sciences(SAVA). Quanterix' sole responsibility with regard to this clinical study was to perform sample testing, specifically, to measure levels of p-tau in plasma samples collected from study subjects.
"To ensure data integrity, it is standard industry practice to keep separate the people who generate the data from the people who analyze the data," said Remi Barbier, President & CEO. "That certainly was the case here. Anything different is a distortion of the facts."
Quanterix' sample testing was conducted entirely by its employees. Quanterix' employees were blind to treatment group, i.e., they did not know which samples were from placebo, or simufilam-treated patients. Quanterix conducted sample testing, then sent raw data to Cassava Sciences(SAVA) for analysis of treatment effects. Eventually, Cassava Sciences(SAVA) presented these data in a poster presentation at the Alzheimer's Association International Conference(AAIC) in July 2021. In keeping with scientific authorship guidelines, prior to submitting the abstract to AAIC, Cassava Sciences(SAVA) received permission from Quanterix to include its lab personnel in the author list.
Cassava Sciences (SAVA) is aware of allegations that are being made by a party that yesterday admitted it holds a short position in the Company's stock. (A short position allows an investor to profit from a drop in the Company's stock price.) Cassava Sciences(SAVA) believes claims made by this party regarding scientific integrity are false and misleading. The Company stands behind its science, its scientists and its scientific collaborators, and is responding to ensure the facts are known and respected.
GLOBENEWSWIRE 10:31 AM ET 8/27/2021
AUSTIN, Texas, Aug. 27, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc.(SAVA) , a biotechnology company focused on Alzheimer's disease, today released a statement regarding plasma p-tau analysis from a previously disclosed randomized, controlled Phase 2b clinical study in patients with Alzheimer's disease. For this study, Cassava Sciences(SAVA) contracted with Quanterix Corp., a highly regarded, independent laboratory, to perform sample testing on blinded samples.
The Phase 2b clinical study was conducted by Cassava Sciences(SAVA). Quanterix' sole responsibility with regard to this clinical study was to perform sample testing, specifically, to measure levels of p-tau in plasma samples collected from study subjects.
"To ensure data integrity, it is standard industry practice to keep separate the people who generate the data from the people who analyze the data," said Remi Barbier, President & CEO. "That certainly was the case here. Anything different is a distortion of the facts."
Quanterix' sample testing was conducted entirely by its employees. Quanterix' employees were blind to treatment group, i.e., they did not know which samples were from placebo, or simufilam-treated patients. Quanterix conducted sample testing, then sent raw data to Cassava Sciences(SAVA) for analysis of treatment effects. Eventually, Cassava Sciences(SAVA) presented these data in a poster presentation at the Alzheimer's Association International Conference(AAIC) in July 2021. In keeping with scientific authorship guidelines, prior to submitting the abstract to AAIC, Cassava Sciences(SAVA) received permission from Quanterix to include its lab personnel in the author list.
Cassava Sciences (SAVA) is aware of allegations that are being made by a party that yesterday admitted it holds a short position in the Company's stock. (A short position allows an investor to profit from a drop in the Company's stock price.) Cassava Sciences(SAVA) believes claims made by this party regarding scientific integrity are false and misleading. The Company stands behind its science, its scientists and its scientific collaborators, and is responding to ensure the facts are known and respected.
GMVD volume picking up
Charismatic Megafauna
Joined:
May 22, 2017
Posts:
7,972
How long do you want to ignore this user?
AG
Spoony Love said:
Any chance their is a late run with MSFT?
Lotto style $302.50 sitting at .06 right now seems like very little downside but maybe huge upside? It keeps pressing down today though.
You SOB I'm in!
Also sava 65c for .35
Can we rename it degenerate Friday?
PLTR brushing off the FBI data breachpushing 26 now and making its way back to test that 27.50 resistance.
I want to drop that short seller off outside the gates at the Kabul airport.Double_Bagger said:
Cassava Sciences Releases Statement Regarding Plasma p-tau Analysis from a Previously Disclosed Phase 2b Clinical Study in Alzheimer's Patients
GLOBENEWSWIRE 10:31 AM ET 8/27/2021
AUSTIN, Texas, Aug. 27, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc.(SAVA) , a biotechnology company focused on Alzheimer's disease, today released a statement regarding plasma p-tau analysis from a previously disclosed randomized, controlled Phase 2b clinical study in patients with Alzheimer's disease. For this study, Cassava Sciences(SAVA) contracted with Quanterix Corp., a highly regarded, independent laboratory, to perform sample testing on blinded samples.
The Phase 2b clinical study was conducted by Cassava Sciences(SAVA). Quanterix' sole responsibility with regard to this clinical study was to perform sample testing, specifically, to measure levels of p-tau in plasma samples collected from study subjects.
"To ensure data integrity, it is standard industry practice to keep separate the people who generate the data from the people who analyze the data," said Remi Barbier, President & CEO. "That certainly was the case here. Anything different is a distortion of the facts."
Quanterix' sample testing was conducted entirely by its employees. Quanterix' employees were blind to treatment group, i.e., they did not know which samples were from placebo, or simufilam-treated patients. Quanterix conducted sample testing, then sent raw data to Cassava Sciences(SAVA) for analysis of treatment effects. Eventually, Cassava Sciences(SAVA) presented these data in a poster presentation at the Alzheimer's Association International Conference(AAIC) in July 2021. In keeping with scientific authorship guidelines, prior to submitting the abstract to AAIC, Cassava Sciences(SAVA) received permission from Quanterix to include its lab personnel in the author list.
Cassava Sciences (SAVA) is aware of allegations that are being made by a party that yesterday admitted it holds a short position in the Company's stock. (A short position allows an investor to profit from a drop in the Company's stock price.) Cassava Sciences(SAVA) believes claims made by this party regarding scientific integrity are false and misleading. The Company stands behind its science, its scientists and its scientific collaborators, and is responding to ensure the facts are known and respected.
Charismatic Megafauna
Joined:
May 22, 2017
Posts:
7,972
How long do you want to ignore this user?
AG
Mvis on a mission
it moved before I could post. Scalping QQQ 375C long here
You don’t trade for money, you trade for freedom.
please tell me you guys bought CEI
You don’t trade for money, you trade for freedom.
Farmer @ Johnsongrass, TX
Joined:
Sep 25, 2017
Posts:
5,415
How long do you want to ignore this user?
Boom-shaka-laka-boom!
ETA: 10:52AM - Everything we discussed on pages 4401 and 4402 this morning are noted in that SAVA press release. Yes, TexAgs knows things..
ETA: 10:52AM - Everything we discussed on pages 4401 and 4402 this morning are noted in that SAVA press release. Yes, TexAgs knows things..
SPY 449C, very tight stop (10%).
You don’t trade for money, you trade for freedom.
set your stop to B/E and trail.$30,000 Millionaire said:
SPY 449C, very tight stop (10%).
You don’t trade for money, you trade for freedom.
you're welcome.$30,000 Millionaire said:set your stop to B/E and trail.$30,000 Millionaire said:
SPY 449C, very tight stop (10%).
You don’t trade for money, you trade for freedom.
Featured Stories
See All
Ags host Buckeyes with an early-season Quad 1 opportunity at stake
by Olin Buchanan
Players to Watch: No. 15 Texas A&M vs. New Mexico State
by Olin Buchanan
8:22
15h ago
1.6k
34:11
10h ago
692
Reed Report: Preparing for Friday's marquee showdown vs. Ohio State
by Luke Evangelist
Bid on Legacy Club tickets to Saturday's Texas A&M vs. NMSU game!
by Texas Aggies United